How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Dupilumab for treating severe chronic rhinosinusitis with nasal polyps

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about dupilumab

Marketing authorisation indication

2.1

Dupilumab (Dupixent, Sanofi) is indicated 'as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe CRSwNP [chronic rhinosinusitis with nasal polyps] for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control'.

Price

2.3

Dupilumab costs £1,264.89 per pack of 2 prefilled pens or prefilled syringes (excluding VAT, BNF online accessed July 2025). The company has a commercial arrangement, which would have applied if dupilumab had been recommended.

Carbon Reduction Plan

2.4

Information on the Carbon Reduction Plan for UK carbon emissions for Sanofi will be included here when guidance is published.